Form 4: Shuttle Pharma Director Granted 29,240 RSUs

Shuttle Pharmaceuticals Holdings, Inc. director George Scorsis was granted 29,240 Restricted Stock Units, vesting over three years.

Summary

• George Scorsis, a Director of Shuttle Pharmaceuticals Holdings, Inc. (SHPH), was granted 29,240 Restricted Stock Units (RSUs).
• Each RSU represents the contingent right to receive one share of common stock.
• The transaction date for this grant was August 8, 2025.
• The RSUs will vest in three equal installments, with one-third vesting on August 8, 2026, August 8, 2027, and August 8, 2028, respectively.
• Following this transaction, George Scorsis beneficially owns 29,240 derivative securities (RSUs).
• 墾],
• positives": [ "The grant of Restricted Stock Units to a director aligns their interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The multi-year vesting schedule encourages long-term commitment and retention of key board members.

Sentiment

Score: 6

Explanation: The grant of RSUs to a director is a routine compensation event that aligns the director's interests with shareholders. It indicates continued commitment from the board member. While it involves future dilution, it's a standard practice for incentivizing long-term performance.

Negatives

• The issuance of RSUs, upon vesting, will result in a slight dilution of existing shareholders' equity, although the amount is relatively small.

Risks

• No specific new risks are identified in this Form 4 filing beyond the inherent risks associated with equity-based compensation (e.g., dilution).

Future Outlook

The vesting schedule indicates a future commitment of the director to the company through August 2028, aligning their long-term interests with company performance.

Industry Context

Equity compensation, such as RSU grants, is a standard practice across various industries, including biotechnology and pharmaceuticals, to attract, retain, and incentivize directors and executives by linking their compensation to company performance.

Comparison to Industry Standards

• The grant of Restricted Stock Units to directors is a common form of non-cash compensation in publicly traded companies, particularly in the biotechnology sector, which often uses equity to conserve cash.
• Multi-year vesting schedules, like the three-year schedule for these RSUs, are standard practice to promote long-term alignment and retention, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for their board members.
• The specific number of units (29,240) would need to be evaluated against the director's overall compensation package and the company's market capitalization to assess its relative size, but without that context, it appears to be a routine grant.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to George Scorsis, a director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential minor future dilution upon vesting of RSUs; improved alignment of director's interests with shareholder value.

Next Steps

• Vesting of 9,747 RSUs on August 8, 2026.
• Vesting of 9,747 RSUs on August 8, 2027.
• Vesting of 9,746 RSUs on August 8, 2028.

Key Dates

Keywords

Shuttle Pharmaceuticals, SHPH, George Scorsis, Restricted Stock Units, RSU, Director Compensation, Equity Grant, SEC Form 4, Beneficial Ownership